Latest filings (excl ownership)
10-K/A
2023 FY
Annual report (amended)
29 Apr 24
8-K
Entry into a Material Definitive Agreement
29 Apr 24
8-K
Entry into a Material Definitive Agreement
24 Apr 24
10-K
2023 FY
Annual report
16 Apr 24
8-K
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
11 Apr 24
8-K
Entry into a Material Definitive Agreement
5 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Entry into a Material Definitive Agreement
27 Mar 24
8-K
Other Events
20 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
15 Mar 24
8-K
Entry into a Material Definitive Agreement
22 Feb 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
16 Feb 24
8-K
Entry into a Material Definitive Agreement
12 Feb 24
8-K
Departure of Directors or Certain Officers
8 Feb 24
8-K
Entry into a Material Definitive Agreement
22 Jan 24
8-K
Entry into a Material Definitive Agreement
11 Jan 24
8-K
Entry into a Material Definitive Agreement
8 Jan 24
8-K
Other Events
28 Dec 23
8-K
NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease
27 Dec 23
8-K
Entry into a Material Definitive Agreement
27 Dec 23
S-1/A
IPO registration (amended)
15 Dec 23
S-1/A
IPO registration (amended)
29 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights
14 Nov 23
8-K
Regulation FD Disclosure
30 Oct 23
8-K
Other Events
24 Oct 23
S-1
IPO registration
19 Oct 23
8-K/A
Financial Statements and Exhibits
19 Oct 23
8-K
Index to Financial Statements
5 Oct 23
8-K
Entry into a Material Definitive Agreement
29 Sep 23
25
Voluntary exchange delisting
29 Sep 23
CERT
Certification of approval for exchange listing
29 Sep 23
8-K
Submission of Matters to a Vote of Security Holders
29 Sep 23
8-A12B
Registration of securities on exchange
29 Sep 23
424B3
Prospectus supplement
22 Sep 23
425
Business combination disclosure
22 Sep 23
8-K
Entry into a Material Definitive Agreement
22 Sep 23
425
Business combination disclosure
22 Sep 23
8-K
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting
22 Sep 23
424B3
Prospectus supplement
21 Sep 23
Latest ownership filings
4
Kathleen D. Scott
14 Feb 24
4
Yong Man Kim
14 Feb 24
4
Paul Y. Song
14 Feb 24
4
Pierre Gagnon
14 Feb 24
4
Michael Klowden
14 Feb 24
SC 13G
METEORA CAPITAL, LLC
14 Feb 24
SC 13G/A
Radcliffe Capital Management, L.P.
14 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
SC 13D/A
NKMAX Co., Ltd.
19 Dec 23
4
Sangwoo Park
15 Dec 23
4
Paul Y. Song
7 Dec 23
4
Paul Y. Song
5 Dec 23
4
James A Graf
5 Dec 23
4
Paul Y. Song
28 Nov 23
4
James A Graf
22 Nov 23
4
Paul Y. Song
22 Nov 23
SC 13D
NKMAX Co., Ltd.
10 Oct 23
3
Michael Klowden
10 Oct 23
3
Kathleen D. Scott
10 Oct 23
3
Alana B. McNulty
10 Oct 23
3
Pierre Gagnon
10 Oct 23
3
Yong Man Kim
10 Oct 23
3
Paul Y. Song
10 Oct 23
3
Sangwoo Park
10 Oct 23
4
James A Graf
4 Oct 23
SC 13G
Radcliffe Capital Management, L.P.
23 May 23
SC 13G/A
HIGHBRIDGE CAPITAL MANAGEMENT LLC
25 Jan 23
3
Sterling Cross
12 May 22
SC 13G
Graf Acquisition Partners IV LLC
11 Feb 22
SC 13G/A
HIGHBRIDGE CAPITAL MANAGEMENT LLC
3 Feb 22
4
James A Graf
14 Jul 21
3
ALEXANDRA LEBENTHAL
14 Jul 21
SC 13G
HIGHBRIDGE CAPITAL MANAGEMENT LLC
9 Jul 21
SC 13G
ADAGE CAPITAL PARTNERS GP, L.L.C.
4 Jun 21
4
James A Graf
3 Jun 21
4
James A Graf
2 Jun 21
4
James A Graf
27 May 21
4
Gus Garcia
26 May 21
4
James A Graf
25 May 21
3
Anatolio B Cruz III
20 May 21